Recent Finacing
Recent Raise
ElsaLys Biotech develops therapeutic monoclonal antibodies for oncology and ophthalmology, converting academic targets into drug candidates via an in-house R&D platform and academic partnerships, including anti-CD160 and anti-TYRO3.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
